Lord's Mark Industries Limited has achieved a significant milestone in the healthcare sector with the launch of the world's first cost-optimised AI-powered hemodialysis centre at Shakti Hospital, Ahmedabad. The development was disclosed to stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, dated 04th May 2026. At the heart of this centre is the Lord's Renal Renalyx Machine, described as India's first indigenously developed smart AI-based cost-effective hemodialysis system, reinforcing the country's Make in India initiative in advanced medical device manufacturing.

Technology and Clinical Features

The Renalyx Machine integrates AI, IoT, and cloud connectivity to deliver real-time monitoring and predictive clinical insights. The system is equipped with a comprehensive set of clinical capabilities designed to enhance patient outcomes and operational efficiency. Key features of the machine include:

• Personalized dialysis protocols tailored to individual patient needs
• Kt/V tracking for precise dialysis adequacy measurement
• Precise fluid management to ensure patient safety
• Endotoxin filtration for enhanced infection control
• Remote supervision and centralized data access for healthcare providers

The following table summarizes the key parameters of the newly launched centre and the Renalyx Machine:

Strategic and Commercial Impact

The launch carries significant strategic implications for both the company and India's broader medical device ecosystem. By deploying an indigenously developed machine, Lord's Mark Industries aims to reduce the country's dependency on imported dialysis equipment while lowering the total cost of ownership for healthcare providers. The centre is designed for cost efficiency, scalability, and improved clinical outcomes, positioning it as a replicable model for wider deployment across hospitals and dialysis centres nationwide.

On the commercial front, the company has outlined an ambitious expansion roadmap. It plans to establish 50 dialysis centres by March 2027, in addition to pursuing domestic sales and exports of the Renalyx Machine. The company is also in the process of obtaining US FDA approval, which is expected to support its global expansion strategy.

Management Commentary

Mr. Sachidanand Upadhyay, Managing Director of Lord's Mark Industries Limited, commented on the development:

"The Lord's Renal Renalyx Machine represents a fundamental shift in dialysis care by combining intelligent technology, indigenous manufacturing, and affordability. Our vision is to enable scalable, high-quality treatment while positioning India as a global leader in AI-based medical devices."

The launch underscores the company's continued focus on innovation, healthcare accessibility, and technology-driven growth, marking a notable step in its evolution within the advanced medical devices segment.